K Kaushansky - New England Journal of Medicine, 1998 - content.nejm.org Although the cellular physiology of megakaryocyte and platelet production has been understood
for nearly a decade, the humoral basis of this process has remained enigmatic until recently.
"Thrombopoietin — At Last" heralded one editorial 1 when the cloning of the chief ... Cited by 245 - Related articles - BL Direct - All 10 versions
- ►bloodjournal.org J Li, C Yang, Y Xia, A Bertino, J Glaspy, M Roberts, DJ … - Blood, 2001 - Am Soc Hematology In these clinical studies, both recombinant TPOs were safe and not associated with
thrombosis. However, PEG-rHuMGDF was paradoxically associated with the development of
persistent thrombocytopenia (platelet count 100 × 10 9 /L) in 13 of 325 healthy volunteers ... Cited by 225 - Related articles - BL Direct - All 4 versions
- ►hematologylibrary.org - Free from Publisher DJ Kuter, CG Begley - Blood, 2002 - bloodjournal.hematologylibrary.org Thrombocytopenia is a common problem in the management of patients with cancer and other
conditions that affect hematopoietic cells. Thrombocytopenia may be occasionally encountered
with conventional chemotherapy regimens used to treat solid tumors but can be a major ... Cited by 150 - Related articles - BL Direct - All 7 versions
- ►nih.gov [PDF] R Salgado, PB Vermeulen, I Benoy, R … - British journal of …, 1999 - pubmedcentral.nih.gov An interim conclusion of the ongoing translational research concerning tumour angiogenesis
is that obtaining quantitative information of this process in cancer patients seems to add
prog- nostic and predictive power to the currently used tumour staging systems ... Cited by 124 - Related articles - BL Direct - All 4 versions
- ►bloodjournal.org RL Basser, E O'Flaherty, M Green, M Edmonds, J … - Blood, 2002 - Am Soc Hematology Two different forms of thrombopoietin (TPO) have entered clinical trials. 1 One is a recombinant
form of the native molecule (rhTPO) and the other a pegylated, truncated version (pegylated
recombinant human megakaryocyte growth and development factor [PEG-rHuMGDF]) ... Cited by 117 - Related articles - BL Direct - All 7 versions
- ►bloodjournal.org A Kaser, G Brandacher, W Steurer, S Kaser, FA Offner, … - Blood, 2001 - Am Soc Hematology Thrombocytosis can be classified into primary and secondary forms. Whereas primary thrombocytosis
is observed in myeloproliferative syndromes, secondary or reactive thrombocytosis is noted in
numerous clinical situations, 1 especially in association with inflammatory states of either ... Cited by 105 - Related articles - BL Direct - All 4 versions
- ►hematologylibrary.org M Peck-Radosavljevic, M Wichlas, J Zacherl, … - …, 2000 - bloodjournal.hematologylibrary.org After orthotopic liver transplantation (OLT), TPO serum levels increase. 6 , 16 Peripheral platelet
counts increase after the elevation of TPO levels with a lag of several days. 14 These data suggest
reduced TPO production as a major factor for thrombocytopenia in liver disease and ... Cited by 93 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] S Vadhan-Raj, CF Verschraegen, C Bueso- … - Annals of internal …, 2000 - Am Coll Physicians Saroj Vadhan-Raj, MD; Claire F. Verschraegen, MD; Carlos Bueso-Ramos, MD; Hal E.
Broxmeyer, PhD; Andrzej P. Kudelka, MD; Ralph S. Freedman, MD, PhD; Creighton L.
Edwards, MD; David Gershenson, MD; Dennie Jones, MD; Mark Ashby, PhD; and John J. ... Cited by 92 - Related articles - BL Direct - All 4 versions
B Wang, JL Nichol, JT Sullivan - Clinical Pharmacology & Therapeutics, 2004 - nature.com Results: Single intravenous or subcutaneous administration of AMG 531 induced a dose-dependent
increase in platelet count in healthy subjects, with peak platelet count being achieved on days
12 to 16. The highest intravenous dose, 10.0 g/kg, caused a nearly 6-fold increase in ... Cited by 99 - Related articles - All 4 versions
- ►hematologylibrary.org DJ Kuter - Clinical Lymphoma & Myeloma, 2009 - CIG Media Group Introduction Thrombopoietin (TPO) receptor mimetics are now available for the treatment of some
forms of thrombocytopenia. Although first proposed to exist in 1958,1 almost 40 years of arduous
investiga- tion passed before TPO was finally purified and cloned by 5 sepa- rate groups ... Cited by 96 - Related articles - BL Direct - All 7 versions
